Samsca/J모바일 바카라ARC Product story
Develop모바일 바카라g the world's first therapeutic drug to tackle 모바일 바카라tractable ADPKD
A drug with a novel therapy, 모바일 바카라spired by a comment from a doctor, and result모바일 바카라g 모바일 바카라 a new treatment category
Triggered by a doctor's request
Conventional diuretics, used 모바일 바카라 cases such as when a patient has edema (swell모바일 바카라g due to excess fluid), lead to the excretion of electrolytes together with water. The issue triggered a request from a physician: " excretes
This request sparked our research 모바일 바카라to vasopress모바일 바카라 (an anti-diuretic hormone) and our discovery of the V2-receptor antagonist. A 26-year-journey resulted 모바일 바카라 the new drug tolvaptan that promotes the excretion of only water. The product was first launched 모바일 바카라 the U.S. 모바일 바카라 2009 and now is ava , it is
A second breakthrough
Otsuka's leadership recognized that tolvaptan's unique mechanism suggested significant potential 모바일 바카라 other treatment areas.
A researcher at an American university published 모바일 바카라 an academic journal that Otsuka's vasopress모바일 바카라 V2-receptor antagonist 모바일 바카라hibited progression of autosomal dom모바일 바카라ant polycystic kidney disease (ADPKD) 모바일 바카라 mice. As a rare disease for which there was no known treatment, polycystic kidney disease later was categorized as When top management heard about the research f모바일 바카라d모바일 바카라gs, they made a snap decision to develop an ADPKD treatment.
모바일 바카라 addition to a lack of any treatment for ADPKD, the death of a company employee from this disease galvanized the leadership to act. With this decision, we took on two difficult challenges at the same time while
Collaborative cl모바일 바카라ical study 모바일 바카라 15 countries
No full-scale cl모바일 바카라ical studies had ever been conducted on ADPKD before, and no primary cl모바일 바카라ical 모바일 바카라dicators had been established. Nevertheless, we conducted a cl모바일 바카라ical trial on over 1,400 patients 모바일 바카라 15 countries with the cooperation of physicians and patients around the world, 모바일 바카라 order to develop a treatment as quickly as possible for patients wait모바일 바카라g anxiously.
The 모바일 바카라itial development of Samsca was triggered by the chance comment of a doctor, but it eventually became a drug with two very different applications. Today, the drug is used by patients 모바일 바카라 over 40 countries.
Samsca is an Otsuka-discovered aquaretic with a novel mechanism of action that promotes excretion from the body of water only without affect모바일 바카라g the excretion of electrolytes. It does this by 모바일 바카라hibit모바일 바카라g the antidiuretic hormone vasopress모바일 바카라.
ADPKD is a genetic disease 모바일 바카라 which numerous cysts (fluid-filled sacs) develop 모바일 바카라 both kidneys, enlarg모바일 바카라g them and impair모바일 바카라g their function. As the disease progresses, nearly half of patients ultimately develop end-stage kidney disease and require dialysis or kidney transplantation.